Why These 15 Healthcare Stocks Are Surging in 2025

Page 9 of 14

6. DBV Technologies SA (NASDAQ:DBVT)

Number of Hedge Fund Holders In Q4 2024: 5

DBV Technologies SA (NASDAQ:DBVT) is a clinical-stage biopharmaceutical company developing non-invasive, self-administered therapies for food allergies, most notably the Viaskin Peanut Patch for children.

The stock is up significantly so far in 2025 as the company announced a pivotal agreement with the FDA. The FDA accepted positive safety data from the VITESSE Phase 3 study and allowed DBV to bypass an additional COMFORT trial, fast-tracking its Biologics License Application for the Viaskin Peanut Patch. This outcome could accelerate the product’s market release by up to a year and significantly de-risk the regulatory path.

On the same day, DBV Technologies also secured up to $306.9 million in new financing, with $125.5 million received immediately and the remainder contingent on warrant exercises. This capital infusion was earmarked to support the Viaskin Peanut program, regulatory submissions, and potential commercialization, but it came with the caveat of significant dilution for existing shareholders.

The consensus price target of $22.5 implies 163.77% upside.

DBVT stock is up 176.05% year-to-date.

Page 9 of 14